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Abstract 
Over the past 20 years, the ethical concerns associated with embryonic stem cell research (ESCR) have 
been the source of great debate. Due to the promise of ESCR, many jurisdictions have introduced 
regulations to govern it. Despite this, Irish policymakers have failed to introduce legislation to regulate 
ESCR and embryo research. Successive calls for legislation were ignored until the publication of the 
General Scheme of the Assisted Human Reproduction Bill 2017 in October 2017. Although the 
publication of the Heads of this Bill is welcomed, there have been no attempts to assess the current 
regulatory framework and its impact on the development of stem cell research in Ireland. To address 
this vacuum, empirical research was conducted with scientists, regulators and funders to explore the 
current regulatory framework in Ireland. This paper reports on and discusses the findings of these 
interviews and critically reviews the 2017 Bill. 
Introduction 
Since the announcement of the creation of the first embryonic stem cell line in 1998, embryonic stem 
cell research (ESCR) has been the source of considerable debate worldwide. To grapple with these 
legal and ethical issues, numerous bioethics councils and individual governments have commissioned 
reports to consider the scientific, legal and ethical issues, and various legislative schemes have been 
introduced to oversee the research. Although the status of the embryo will be an ever-present topic, 
it is no longer the only concern in the regulation of ESCR. The conversation has now moved to the risk-
benefit ratio and distributive justice,1 and conservations have begun to focus on the ethical and legal 
implications of human embryo genome editing.2 Despite this progress in science, Irish policymakers 
have failed to introduce legislation to regulate ESCR and embryo research. Successive calls for 
legislation were ignored until the publication of the General Scheme of the Assisted Human 
Reproduction Bill 2017 (the “GSAHR Bill 2017”) in October 2017.  
Attempts to bring legislative clarity are welcomed, but there has been no attempt to assess the current 
regulatory framework and its impact on the development of stem cell research in Ireland. This paper 
seeks to address this vacuum. It will provide a brief overview of the status of the embryo and ESCR in 
Ireland and provide a basis for this study. Key findings of the interviews will be presented and 
discussed in light of the GSAHR Bill 2017. It will conclude with some commentary on the GSAHR Bill 
2017 and recommendations for change before it becomes law. 
Status of Embryonic Stem Cell Research in Ireland 
                                                          
1 G. Cossu et al., “Lancet Commission: Stem cells and regenerative medicine” (2018) 391(10123) Lancet 883–
910. 
2 D. Pei et al., “Human Embryo Editing: Opportunities and Importance of Transnational Cooperation” (2017) 
21(4) Cell Stem Cell 423–426. 
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Until May 2018, the “unborn” in Ireland was constitutionally protected by virtue of the Eighth 
Amendment to the Constitution—Art.40.3.3°. The purpose of the amendment was to constitutionally 
prohibit abortion, but it contained no reference to abortion. Rather, the Eighth Amendment 
introduced the undefined term “unborn” into the Constitution, resulting in much uncertainty as to its 
scope, including whether it encompassed the embryo in vitro. During parliamentary debates, little 
consideration was given to its possible implications on embryos in vitro. Such an omission was a 
considerable oversight considering the birth of Louise Brown—the first person born through in vitro 
fertilisation (IVF)—had occurred in 1978, and it was known that embryos could be developed outside 
of the womb. A proposed amendment by (the then) Senator Catherine McGuinness—a member of 
the opposition in the Seanad—to explicitly state that constitutional protection applies after 
implantation would have clarified that constitutional protection applied to embryos in vivo only, but 
this was rejected.3  
Despite the Attorney General’s criticism of the wording of the amendment,4 and the lack of legal 
advice sought prior to the publication of the amendment,5 it was ultimately passed. The prediction 
that the amendment would open a “legal Pandora’s Box”6 came to fruition, and in the following 
decades, the courts have been occupied with abortion and circumstances in which it is constitutionally 
permissible to have an abortion in Ireland. The Protection of Life During Pregnancy Act 2013 came 
after a series of High Court, Supreme Court and European Court of Human Rights judgments in which 
there were successive calls for clarification within this context.7  
The possible impact of Art.40.3.3° on embryos in vitro was largely ignored until the Constitution 
Review Group called for a definition to clarify, amongst other things, the impact of the Eighth 
Amendment on assisted reproductive technologies and, by implication, ESCR.8 Aware of the growing 
need to regulate assisted reproductive technologies, the government appointed the Commission on 
Assisted Human Reproduction (CAHR) in 2000.9 Its 2005 report, and a subsequent report by the Irish 
Council for Bioethics (ICB) in 2008, considered the legal status of the embryo.10 Both groups were of 
the view that, although the matter would need clarification from the Supreme Court, the embryo in 
vitro is not protected under Art.40.3.3°.  
Clarification came in Roche v Roche11 when the High Court and Supreme Court were asked to consider 
whether the protection under Art.40.3.3° extended to embryos in vitro. Both courts recognised the 
difficulty in determining the status of the embryo, as it requires choosing one moral viewpoint over 
another in a debate that may have no common agreement. McGovern J. in the High Court noted that 
“[t]he fact that something is not prohibited by the law does not of itself mean that it is morally 
                                                          
3 Seanad Debates 1983, vol.100, col.1092. 
4 “Attorney General Rules Out Wording”, The Irish Times 16 February 1983, p.6. 
5 “Abortion Text Not Yet Available”, The Irish Times, 16 March 1983, p.5. 
6 Máire Geoghegan-Quinn TD, Dáil Debates 2 March 1983, vol.340, col.1622. 
7 Attorney General v X [1992] 1 I.R. 1; A and B v Eastern Health Board [1998] 1 I.R. 464; A, B and C v Ireland 
(2011) 53 E.H.R.R. 13. 
8 Constitution Review Group, Report of the Constitution Review Group (1996), p.275. The first ESC line was not 
derived until 1998 and thus did not form part of the analysis of the Constitution Review Group. 
9 Commission on Assisted Human Reproduction, Report of the Commission on Assisted Human Reproduction 
(2005). 
10 Irish Council for Bioethics, Ethical, Legal and Scientific Issues Concerning Stem Cell Research (2008).   
11 Roche v Roche [2010] 2 I.R. 321. 
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acceptable to carry out that act”, but the duty of the courts is to implement and apply the law, not 
morality.12  
In holding that the embryo in vitro is not protected under Art.40.3.3°,13 the courts did note that the 
embryo is deserving of respect. The extent of this respect and the protections that society may afford 
to it is not something for the courts to decide, but attention was drawn to the impact that holding that 
the embryo in vitro is the “unborn” may have on widely-used contraceptive practices that permit 
fertilisation but prevention implantation.14 The courts stressed the need to introduce legislation as 
the science will continue to advance.15 Geoghegan J. considered that a continued failure to protect in 
law the embryo “is undesirable and arguably contrary to the spirit of the Constitution”, and the 
Supreme Court noted that should the matter come before the courts again, it would be forced to 
consider the legal status of the embryo.16  
Around this time, University College Cork (UCC) and Trinity College Dublin (TCD) published guidelines 
permitting the use of embryonic stem cells (ESCs), and based their guidelines on the recommendations 
of the ICB report.17 However, accessing funding has proved to be problematic, as the biggest funders 
of science in Ireland—Science Foundation Ireland (SFI) and the Health Research Board (HRB)—have 
been instructed by the Department of Health since 2009 not to fund ESCR until legislation on assisted 
reproduction and associated research is introduced.18 Despite clarification from the Supreme Court 
that there is no constitutional impediment to ESCR in Ireland, this moratorium remains in place. In 
October 2017, the GSAHR Bill was published and it is the first legislative initiative to regulate ESCR in 
Ireland. However, despite the proposed changes, there have been no attempts to date to engage with 
researchers on this matter.  
This study seeks to address this vacuum and it is the first study to explore the impact of the current 
policy on scientific research in Ireland. Since these interviews were conducted, the GSAHR Bill 2017 
was published and thus the findings of this study will inform a discussion on the Bill.  
Methodology 
This was a qualitative research project involving face-to=face in-depth interviews with 16 key 
stakeholders. Using purposive sampling, respondents were selected based on their expertise in stem 
cell research and the regulation of science in Ireland. Other respondents were identified through snow 
                                                          
12 [2010] 2 I.R. 321 at 340. 
13 For critiques of this decision, see W. Binchy, “Article 40.3.3 of the Constitution: Respecting the Dignity and 
Worth of Human Beings” in J. Schweppe (ed.), The Unborn Child, Article 40.3.3° and Abortion in Ireland: 
twenty-five years of protection? (Dublin: The Liffey Press, 2008), p.195. 
13 [2010] 2 I.R. 321 at 347–348. 
14 [2010] 2 I.R. 321 at 383. 
15 [2010] 2 I.R. 321 at 393. 
16 [2010] 2 I.R. 321 at 393. 
17 See Trinity College Dublin, Policy on Good Research Practice (2009) and University College Cork, Code of 
Practice for Research Using Embryonic Stem Cell Lines (2008), available at: 
https://www.ucc.ie/en/news/archive/2014andbeyond/2008pressreleases/ucc-statement-following-governing-
body-meeting-of-28102008-at-which-consideration-was-given-to-embryonic-stem-cell-research-
recommendations.html [accessed 19 November 2018].   
18 SFI Policy on Research Using Human Embryonic Stem Cells, available at: http://www.sfi.ie/funding/sfi-
policies-and-guidance/ethical-and-scientific-issues/ [accessed 9 October 2018]. 
4 
 
balling sampling. Respondents included scientists, geneticists, embryologists, funders of scientific 
research, regulatory bodies and lawyers. 
All respondents, with the exception of three, were based in Ireland. The remaining three comprised 
of one scientist who completed their undergraduate training in Ireland and is now based in the UK 
was interviewed to assess the impact that the current status of ESCR has on their career decisions and 
two lawyers based in the UK who were selected due to their experience working in the legal aspects 
of biotechnology and the life sciences internationally. Although the original intention was to focus on 
scientists, health care professionals and funders, it was deemed necessary to have in-depth 
discussions with lawyers on features of forthcoming legislation.  
The interviews lasted approximately 50 minutes each and took place between April and June 2017. 
After outlining the project and the purpose for the interview, written informed consent for 
participation and recording of the interview was obtained. Interviews explored the status of science 
and funding for science in Ireland, the impact that the current framework has had in Ireland and 
interviewees’ reflections on the regulation of ESCR.  
All interviews were conducted in English, recorded and transcribed verbatim. Data analysis was 
facilitated by using the software Nvivo. A contextualised thematic approach was used to interpret the 
results. This study was approved by the Research Ethics Committees at Middlesex University. 
Results 
The findings of this study paint a worrying picture for the regulation of stem cell research in Ireland. 
National scientific policy was heavily criticised by the scientists as being short-sighted. They confirmed 
that ESCR is not currently taking place in Ireland and that there is an inconsistency in the treatment of 
the differing cells and tissues used for research in Ireland. The findings revealed that the lack of 
regulations for ESCR has had a negative impact on research in Ireland, specifically induced pluripotent 
stem cell (IPSC) research, as well as an impact on the development of the careers of many of the 
respondents. All respondents called for clarity and transparency in this area in the form of legislation 
as well as the re-establishment of an independent national bioethics framework.  
Status of ESCR in Ireland 
It is clear from these interviews that no ESCR is currently ongoing in Ireland. Respondents confirmed 
that there is no public funding available for ESCR in Ireland and this includes European funding (such 
as Horizon 2020 or European Research Council funding), as this falls under exchequer funding. The 
Irish funding bodies have collaborations with international bodies such as the National Institutes of 
Health (NIH) in the US and the Wellcome Trust in the UK, and the Memorandum of Understanding 
between these bodies excludes ESCR from the funding remit. Funders made it clear that these 
prohibitions will remain in place until such time as legislation permitting ESCR is introduced.  
Pertaining to the private funding of ESCR, it was felt that the lack of medical charities investing in 
research and development in Ireland, compared to the rest of the world, hampered access to other 
forms of funding. Respondents who did want to pursue ESCR felt that they were unlikely to get other 
forms of external funding while the legal uncertainties remain.  
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We can be part of European projects, where other partners in their own countries, where the 
legislation is different, can do embryonic stem cell work, we can't and our researchers can't. 
(03, Funder) 
If you're going up against other European countries that have solid stem cell legislation, you're 
more likely to not get funded … you can't have a national standard of stem cell research, you 
really have to have an international standard … that would be having access to all the same 
cell types that other countries have under strict supervision. (02, Scientist) 
Many respondents were highly critical of the unwillingness of the government to engage in many 
difficult and complex scientific areas such as ESCR and assisted human reproduction (AHR), and there 
was consistent criticism amongst respondents of the (at that time) ongoing failure to provide a 
legislative solution. Attention was drawn to bodies such as the Health Products Regulatory Authority 
(HRPA), but this body manages the service and quality management system of AHR and associated 
research; thus, oversight of the difficult ethical questions pertaining to AHR remain. 
Incoherence, Inconsistency and Academic Freedom 
Throughout the interviews, respondents were critical of the current funding framework for science 
and ESCR policy in Ireland. In particular, there were four criticisms and concerns. 
First, amongst the scientists there was widespread criticism of the current funding policy for science 
generally. Although funders noted that their budgets had not decreased after the economic downturn, 
the focus has shifted away from the funding of fundamental science. The focus of the main funding 
bodies in Ireland is applied research—a move respondents felt has been driven by the Government 
and supported by industry, with the aim of job creation. Although it was noted that this is a trend 
across the world, in Ireland there is a real lack of funding for fundamental research. Respondents felt 
that this is problematic, as fundamental research feeds applied research; thus, the funding of 
fundamental science is necessary to fuel the research cycle. Without this, Ireland is failing to build a 
self-sustaining system for research. Many also felt that this policy has led to difficulty in attracting and 
retaining good researchers. Almost all scientists reflected that they would not have achieved their 
successes in the current funding environment, and likely would not remain in Ireland if they were an 
early career researcher.  
Our budget did not decrease with the economic downturn, which was obviously very 
favourable.  (02, Funder) 
They don’t realise that many of the best discoveries in medicine and science come about by 
simply very good scientists just having inquisitive minds. (01, Scientist) 
Secondly, the inconsistencies in policies pertaining to different cells were criticised. It was noted that 
research using both foetal cells and human embryonic kidney (HEK) cells is currently ongoing and 
publicly funded in Ireland. Foetal cells are generally acquired abroad and can come from an aborted 
foetus or a miscarriage, while a HEK cell is an immortalised cell line that originated from a HEK. 
Respondents felt that a policy that funds HEK cell and foetal cells research but prohibits the funding 
of ESCR is illogical, but likely due in part to a lack of understanding of the different types within the 
Department of Health.  
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This is a cell that’s derived from a human embryonic kidney cell ... it is from a human embryo 
and yet people would be very concerned about using human embryonic stem cells, but not 
human cells that come from an embryonic kidney and these cells are being used and there's 
no impediment to use them. (05, Scientist) 
It has to be said that every virology lab in the State uses embryonic cells and they have the 
same considerations that embryonic stem cells have, but we can use them willy-nilly, without 
any regulation. (07, Scientist) 
Thirdly, in discussing the ban on ESCR, some felt that this policy had a negative effect on IPSC research 
in Ireland. It was clear from discussions that Ireland is active both in adult stem cell research and IPSC 
research. One respondent reflected that perhaps the development of IPSC research has done away 
with the need to consider the ethics of ESCR in Ireland. For the remainder of respondents, it was a 
scientific issue; discussions focused on the inability to use ESCs as a control and whether this was a 
dis-service to Irish researchers. Those currently using IPSCs did not feel that they were disadvantaged 
and the funders noted that all applications went through international peer review and were approved 
to be of the highest standards. However, the majority of researchers did feel that, for research using 
IPSCs, an ESC control is necessary.  
I mean and that is our concern generally about this area, that we think, that these are 
workarounds. But they're not ideal workarounds and it would be much better if you could have 
the whole suite … it’s just that there's not a whole pile we can do about it at the moment … 
unfortunately our hands are tied in this and I mean, the researchers themselves have concerns 
about this as well, but until somebody has the balls to actually take this legislation and sort it 
out, we really are hamstrung, which is a shame. (03, Funder) 
Of course you need to use an embryonic control ... otherwise you're not comparing like with 
like, you have no idea. (06, Scientist) 
Finally, in discussing funding generally, the funders made it clear that outside of targeted calls for a 
specific area of research, they do not dictate to researchers what research to do. However, for those 
who did wish to use ESCs, it was clear that the lack of funding had impacted their decisions on their 
own career paths. They felt that this had negatively impacted them as “there’s a clear piece missing”. 
The funders did highlight that even if there was no moratorium from the Department of Health on the 
funding of ESCR, it could still fall under the internal rule that has seen a move away from the funding 
of fundamental to applied research. 
I was just put off by the fact that there's a sort of grey … I'd never have got it through the 
internal ethics processes because there was no external framework for them to work to. (03, 
Scientist) 
Throughout the discussions with the scientists, it was clear that they had to restructure their research 
due to the funding rules surrounding fundamental research and ESCR. For those who had wished to 
pursue ESCR, this was felt more starkly. The funders did acknowledge that it is possible to secure 
funding for fundamental research either through international funding bodies, one of the co-funded 
schemes with international partners, or “sneak in a bit of fundamental into their applied project”. 
However, it is not currently possible to access funding for ESCR. One respondent felt that the current 
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funding ban impinges on his right to academic freedom under the Universities Act 1997. Even if private 
funding could be sourced, some respondents felt that Irish universities are risk averse and likely to be 
too concerned with the exposure and potential political implications of such research to permit it to 
proceed. 
Funding agencies can decide what they want to fund … that’s true up to a point … but to get 
down to individual cell lines and say, you can use this cell line but you can't use that one, that’s 
something that has never done and that’s political interference, pure and simple. (08, Scientist) 
They may want to do it but their institutions may be deterred from allowing them to do it 
because of the concerns about what might happen and the political ramifications. (01, Clinical 
geneticist) 
Clarity and Transparency  
The need for clear and transparent structures for ESCR and science generally was a consistent theme 
throughout all interviews and can largely be grouped into: clarity and transparency through legislation; 
a regulatory framework; and a national bioethics council. 
(1) Legislation 
In reflecting upon possible legislation, all respondents stressed the need for clarity and transparency. 
Clarity was necessary regarding the boundaries of permitted research, but also regarding the 
permissibility of future therapies arising from ESCR. It was felt that this is necessary for public 
confidence in the system. Many respondents noted the importance of ensuring that any legislation be 
harmonised with the European standard, and that a national standard of stem cell research should be 
avoided in favour of an international standard to improve chances of international funding success.  
So, I think that, you know, on a number of fronts, in terms of like scientific integrity, in terms 
of value for money for taxpayers’ investment and in terms of soliciting more international 
investment, you need to have transparency and transparency is given through regulation. (02, 
Scientist) 
I think it would need to be consistent with what is deemed best practice in other European 
countries. (03, Scientist) 
Respondents felt that critical issues, such as the status of the embryo, what can be done with an 
embryo, source of ESCs, and the permitted purpose of research must be clarified. When probed on 
this matter, respondents found it difficult to select a cut-off point for research on the embryo. 
Different biological makers, such as the appearance of the neural tube and differing cut-off points 
such as day 10, 14 or 18 were noted as possibilities. They also had difficulty in defining an embryo, 
feeling that both matters should be left to the “lawyers”. 
I think issues around consent in terms of, as I say and it always seems to boil down to the 
generation of the cell lines, so I think that it would be very important to see strong issues 
around consent … I think there would have to be very clear guidelines within the legislation 
about the circumstances under which eggs could be harvested, or under which embryos could 
be used, you know and that they would have, so I think it would be more around the guidelines 
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and the criteria as to what would actually qualify under the legislation as an embryonic stem 
cell line that could be used for research. (01, Funder) 
Try to define an embryo, good luck is all I can say, because there's, you know, I think people 
will have trouble defining exactly what an embryo is, because conception or fertilisation is a 
definite time point, but after that, everything is gradual. So you'll have to say, okay, look, you 
can do research on cells derived from an embryo up to this time point, but I think you might 
get arguments as to what that time point is. (05, Scientist)  
Looking to the future, respondents felt that legislation should also address possible future therapies 
to ensure that they are permitted in Ireland. Such legislation should allow for the testing of certain 
diseases and the provision of therapies. It was noted that even if treatments become available from 
ESCR, Irish policymakers would undoubtedly make these treatments available to patients in Ireland. 
The inconsistency of permitting access to therapies while also prohibiting ESCR was highlighted. 
If there was a treatment for, say, Alzheimer’s Disease, developed tomorrow in the US using 
human embryonic stem cells, at some stage I would see that treatment coming into Ireland. 
So it’s an Irish solution to an Irish problem, where we don’t allow the research ourselves but 
we’re quite happy to benefit from it if it’s done somewhere else. (Voice 11) 
(2) Independent regulatory body 
Respondents considered that some independent body should oversee this research and it should not 
be left to individual institutions. The UK Human Fertilisation and Embryology Authority (HFEA) was 
frequently favourably mentioned as a body that worked well and provided confidence to the public 
by demonstrating that the research is well controlled. The HPRA was also mentioned as a body that 
functions well with clear regulatory oversight.  
I think it probably deserves a separate body like HFEA because it gets quite complex. (01, 
Regulator) 
I think it needs to be national, I think it’s such a big question. I don’t think it’s right or fair or 
appropriate that the universities deal with it on an institutional level. I think it has to be 
considered at a national level. (04, Scientist) 
Such a body could also be tasked to respond to future technological and scientific change, both in the 
area of stem cell research and other emerging technologies that require legal, ethical and scientific 
reflection, such as gene editing and CRISPR technology. As such, the importance of staffing this body 
with experts who can address the complex and interdisciplinary issues was stressed. 
It’s about actually having a proactive regulatory framework versus a reactive one. (02, 
Scientist) 
(3) National Bioethics Council 
During Ireland’s economic downturn, the ICB was disbanded as a purported cost-saving measure. 
Although the National Advisory Committee on Bioethics (NACB) was established within the 
Department of Health in 2012, the closing of the ICB was lamented by many respondents. Although 
this body has been reconstituted into an advisory body for the Department of Health, it was felt that 
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this was a real loss to science in Ireland. It was felt that the NACB lacks independence as, unlike the 
ICB, the Minister for Health is now in charge of setting the agenda. This was perceived to be 
problematic. 
The role that the former Council had in engaging the public on bioethical issues was also noted and 
the reconstituted group no longer has that function. Respondents felt that the ICB had an important 
role in engaging scientists and bioethicists with the public and the closure has left a void. It was also 
felt that the ICB had an important role in demonstrating that bioethics has an important role in the 
governance of science to outside investors. 
In reconstituting something as an advisory group for bioethics for the Department of Health it 
meant the Department of Health sets the agenda. It isn’t that this group could meet and decide 
what are the things they want to do … can't choose its own agenda and set its own reports. 
It’s responding to the Minister, rather than setting up its own independent agenda. (01, Clinical 
geneticist) 
We had seen a gradual development of science regulatory structures … we had seen things like 
the establishment of the Bioethics Council. (02, Scientist) 
Reproductive Health and Embryonic Stem Cell Research 
Respondents were unanimous that abortion is not linked with the regulation of ESCR, but some felt 
that the (then) forthcoming abortion referendum could have an impact on the ESCR debate. The 
abortion debate could make politicians reluctant to introduce legislation on embryo research but, on 
the other hand, some felt that the liberalisation of the laws on abortion could help the passage of 
ESCR regulations. Whatever the impact, some respondents felt that the abortion issue should be 
resolved prior to the introduction of policy on ESCR. 
When asked whether AHR and ESCR should be regulated at the same time, respondents were divided. 
Some felt that although the ethical issues in ESCR and AHR are aligned, as both are dealing with an 
embryo, the purpose of both technologies is different. The purpose of AHR is a successful pregnancy 
while ESCR is focused on research, therefore the ethical considerations are different. 
I think they're utterly different sectors. Just because they happen to involve at some level the 
same type of cell to start with, on the one hand you're talking about allowing people to have 
children and on the other hand, you're talking about scientific use of stem cells. I can't see any 
link between the two, I think they're quite different.  (04, Scientist) 
Respondents who thought that ESCR and AHR should be regulated together based their beliefs on two 
separate considerations. First, in juxtaposition with the previous group, they felt that as both are 
concerned with an embryo, they are inextricably linked. AHR will create many supernumerary 
embryos and a decision must be made as to the use of these embryos. Respondents felt that the use 
of these embryos for research should be a part of this conversation.  
Secondly, some respondents felt that AHR is closely linked with research, and in particular embryo 
research. The historical link between fundamental research and AHR was highlighted and one 
respondent noted that IVF came about from research on embryos. Some respondents also noted that 
we know very little about early embryo development and in fact have a better understanding of the 
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first month of embryo development in mice than in humans. Research on this early embryonic stage 
is important in better understanding the causes of miscarriage and the development of serious 
diseases in utero. Thus, it is important that we do research on embryos up to, and potentially past, 14-
day-old embryos. 
I don’t think you can separate them, because at the end of the day, you're creating life outside 
of the human body and something has to happen with the resulting embryo that doesn’t get 
implanted. (07, Scientist) 
You could say they're separate things, but assisted reproduction should be relying on talking 
to [fundamental] research. (08, Scientist) 
 
Discussion 
Since these interviews were carried out, the GSAHR Bill 2017 has been published. The Bill seeks to 
provide for: the regulation of AHR; gamete and embryo donation for use in AHR treatment and 
research; posthumous assisted reproduction involving the gametes or embryos of a deceased person 
under certain conditions; pre-implantation genetic diagnosis and sex selection; surrogacy; embryo and 
stem cell research; and the establishment of an independent regulatory authority for AHR.  
ESCR, AHR and associated therapies are intended to be regulated under the same legislative scheme. 
Such an approach makes pragmatic sense, but the sheer breadth of issues to consider does raise 
concerns that all issues will not be sufficiently considered. The proposed regulatory framework for 
ESCR has been subject to some academic criticism,19 but since the publication of the GSAHR Bill 2017, 
surrogacy is the issue that has attracted most attention.20  
There have been considerable developments in the realm of embryo research, most notably 
mitochondrial replacement techniques and embryo editing since the publication of the CAHR report 
that have not been discussed in Ireland. The 14-day rule has also become the subject of debate in light 
of scientific developments that now make it possible to culture an embryo beyond this date. The 
germline modification of embryos raises considerable ethical considerations that perhaps should be 
considered, prior to the introduction of any legislation in this area. In the UK, there has been 
considerable scientific, legal and academic discussion as well as public debate on these matters—
conversations that have not taken place in Ireland. Although discussions at the committee stage have 
yet to commence, it is essential that each of these issues receive sufficient discussion and debate. 
Governance of Cells and Tissues in Ireland: An Ongoing Inconsistency 
                                                          
19 C. Staunton, “The regulation of stem cell research in Ireland: From the Commission on Assisted Human 
Reproduction to the Assisted Human Reproduction Bill 2017” (2018) 18(1) Medical Law International 35–58. 
20 B. Tobin, “Surrogacy proposals would make process costly, time consuming and frustrating”, TheJournal.ie, 
27 October 2017, available at: http://www.thejournal.ie/readme/opinion-surrogacy-proposals-would-make-
process-costly-time-consuming-and-frustrating-3666377-Oct2017/ [accessed 9 October 2018]; D. Quinn, 
“Three’s a crowd when it comes to mothers”, The Times, 22 October 2017, available at: 




Prior to the publication of the GSAHR Bill 2017, there was a real moral inconsistency in the treatment 
of embryos. In the intervening years since the court in Roche held that the embryo in vitro has no 
protection in law, successive governments failed to introduce legislation on this matter. It left Ireland 
in the situation whereby there is absolute protection for the embryo in vivo and no protection in law 
for the embryo in vitro. The GSAHR Bill 2017 does remedy this inconsistency and provides some 
protection for the embryo in vitro, but the strict rules on the use of pluripotent stem cells, irrespective 
of the source of these cells, introduces a new and unwarranted inconsistency.  
Foetal cells and HEK cells will continue to be used in Irish laboratories, but not under the strict 
conditions laid down by this Bill. Head 63(2) puts the same restrictions and conditions on IPSCs as ESCs. 
IPSCs are reprogrammed adult stem cells that are pluripotent and have many similar characteristics 
as ESCs.21 These cells do not involve the destruction of an embryo and, as such, do not attract the 
same ethical controversy. The use of these cells has the same ethical consideration as the use of any 
other somatic cell, and attracts less ethical controversy than a foetal or HEK cell. However, the 
justification in the explanatory note for treating IPSCs and ESCs the same is, “while their source (i.e. 
adult somatic cells) is not controversial, the potential uses to which they can be put are similar to 
ESCs”.  The source of ESCs is controversial, but the potential use of these cells is not. It is thus unclear 
why IPSCs whose source and use are relatively free from controversy, will be subject to strict 
regulatory scrutiny simply because the use of IPSCs and ESCs are the same. If the policy is to regulate 
cells based on their potential uses rather than their source, other cell types must be included in this 
regulatory framework. Adult stem cells and tissue cells such as chondrocytes or keratinocytes may 
also be put to the same use,22 and the justification for distinguishing adult stem cells and IPSCs is 
unclear. The inconsistency of this proposed policy change is further highlighted when one considers 
that HEK cells and foetal cells will not be subject to these strict requirements. 
This policy is also out of step with international best practice in this area. In the most recent revision 
of the International Society for Stem Cell Research (ISSCR) Guidelines, it is explicitly stated that as 
IPSCs do not encounter the same ethical sensitivities as ESCs, IPSC research does not require 
specialised review.23 The additional regulatory burden on IPSCs is unnecessary and likely to discourage 
scientists in Ireland from using such cells. 
Governance of Science in Ireland 
In its report on stem cells and regenerative medicine, the Lancet Commission speaks about the 
importance of the social contract with the public in the field of regenerative medicine. It raises the 
concern that poor-quality science, funding models that lack clarity, unrealistic expectations and rogue 
clinics offering false cures are threatening the social licence to conduct such research.24 The Lancet 
Commission recommends that the challenges facing regenerative medicine and stem cell research can 
be resolved by a strategy that involves better science, better funding models, better governance and 
                                                          
21 J. Yee, “Turning Somatic Cells into Pluripotent Stem Cells” (2010) 3(9) Nature Education 25 at 25. 
22 The author expresses gratitude to Prof. Frank Barry for a discussion on this point. 
23 International Association for Stem Cell Research, Guidelines for Stem Cell Research and Clinical Translation 
(2016), para.2.1. 




better public and patient engagement. 25  The findings of this research point to problems in the 
governance of science generally, and in particular the regulation of ESCR in Ireland. It is clear that the 
lack of legal clarity, and the de facto ban on ESCR due to the prohibition of funding for it, has an impact 
on the governance of science, the quality of science in Ireland and the attractiveness of Ireland as a 
research environment.  In considering the findings of this study, one cannot but feel that the social 
licence to conduct ESCR in Ireland, while not completely broken, is in danger of breaking, largely due 
to poor governance of science generally and government inaction on ESCR.  
For Ireland, it is clear from this study that the governance of science is problematic. While heartening 
that the importance of bioethical governance for research was stressed by so many respondents, at 
the heart of the governance problem is the lack of an independent bioethics infrastructure. It is both 
a symptom and a cause of the governance issues: the lack of an independent body deprives us of an 
opportunity to publicly engage in many of the major bioethical issues raised by developments in new 
technologies, but it also speaks volumes about the continued reluctance of Irish policymakers to 
address such issues.   
Article 19 of the UNESCO Declaration on Human Rights and Bioethics talks about the importance of 
an “independent, multidisciplinary and pluralist ethics committee”, both at a local and national level. 
At a local hospital or university level, such committees are required to provide clinical guidance 
(presumably in the form of a clinical ethics committee) and to provide an ethical, legal, social and 
scientific assessment of research (presumably in the form of a research ethics committee). Article 19 
also speaks to the importance of assessing “scientific and technological developments, formulate 
recommendations and contribute to the preparation of guidelines”, and fostering “debate, education 
and public awareness of, and engagement in, bioethics”.  A national bioethics committee thus has a 
role in the development of guidelines, but also in fostering public education and debate.  
The importance of an independent committee is that it will have the necessary expertise and time to 
engage with the issues associated with developments in biotechnology, and can attempt to balance 
the interests of human rights, science and public policy in an environment that should be free from 
political influence.26 However, the task of the Irish National Advisory Committee on Bioethics seems 
to be restricted to supporting the work of the Minister for Health and the Department of Health. Its 
normative function is weak and its role in public engagement non-existent. A body that develops 
opinions in response to a ministerial request can only have a limited role in developing national 
guidelines or stimulating public debate.  
The CAHR and ICB reports are also outdated; the CAHR report did not consider IPSCs and neither 
report considered mitochondrial replacement transfer or gene editing. Independent bioethics councils 
across the globe are developing opinions and policies in these areas, yet Ireland continues to shy away 
from these major bioethical discussions. For a social licence to operate, there must be some public 
understanding of these issues, but the infrastructure in which such a discussion can take place in 
Ireland is lacking. 
                                                          
25 G. Cossu et al., “Lancet Commission: Stem cells and regenerative medicine” (2018) 391(10123) Lancet 883–
910. 
26 E. Petit, “An Ethics Committee for Patent Offices?” in A. Plomer and P. Torremans, (eds), Embryonic Stem Cell 
Patents: European Patent Law and Ethics (Oxford: Oxford University Press, 2010), p.309. 
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The developing discussion on the GSAHR Bill 2017 is likely to attract controversy that could at times 
be mired in misconceptions and untruths. An independent body can provide sound legal, ethical and 
scientific advice, free from the polarising rhetoric that is too often a feature of these debates. This is 
necessary for public debate, but also importantly for the legislature. While the Human Fertilisation 
and Embryology Act 1990 parliamentary debates were ongoing in the UK, the Voluntary Licensing 
Authority (VLA)27 was established to issue licences and provide a minimum set of standards that clinics 
should follow in the interim. The VLA also took it upon itself to educate Members of Parliament about 
the science behind IVF. This was in response to a concern that the parliamentarians would be 
influenced by media reports that depicted IVF as growing foetuses in test tubes. 28  Furthermore, 
without an independent body that seeks to consider the legal, ethical and social issues with new 
technologies, Ireland will continue to have a reactive rather than a proactive regulatory regime.  
Conclusion 
The development of stem cell legislation has been long-awaited. Currently, national agencies will not 
fund the research and the lack of legislation and national ethical oversight means other international 
agencies will not fund. The GSAHR Bill 2017 provides some clarity, but problems nevertheless remain. 
There is a continued inconsistency in the treatment of cells in Ireland, and the proposed legislation 
will bring unnecessary regulation to the use of IPSCs—cells that are generally perceived to be ethically 
uncontroversial. Wider governance issues also remain and the establishment of an independent 
bioethics council, with an engagement function, is necessary in Ireland. It is clear that before the 
GSAHR Bill 2017 becomes law in Ireland, Irish policymakers must consider the wider ethical and 
economic governance problems associated with science in Ireland.  
                                                          
27 This was later renamed the Interim Licensing Authority until it was named the Human Fertilisation and 
Embryology Authority under the 1990 Act. 
28 J Gunning & V English, Human IVF: A Case Study on the Regulation of Medical Innovation (Dartmouth 1993) 
57. 
